Trading Statement

RNS Number : 7647P

Allergy Therapeutics PLC

22 July 2010

 



Thursday 22 July 2010

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

Notification of Preliminary Results and Trading update

Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, will announce its preliminary results for the year ended 30 June 2010 on 20 September 2010. The Company expects to report revenue of approximately £40.7m (2009: £37.8m); broadly in-line with current market expectations.

Significantly, for the first time as a public company, Allergy Therapeutics expects to post an operating profit for the financial year ended 30 June 2010 (2009: loss of £6.2m). Full details of the company's performance will be made available in the preliminary announcement.

Commenting on the trading update, Manuel Llobet, CEO of Allergy Therapeutics said:

"This is great news for the Company, posting its maiden operating profit and will be a landmark in the Company's performance"

For further information

Allergy Therapeutics	[phone]
Ian Postlethwaite Finance Director
Manuel Llobet Chief Executive Officer
www.allergytherapeutics.com
Nomura Code Securities	[phone]
Juliet Thompson/ Clare Terlouw

 

END

 

 

TSTZMGZNMZZGGZM